Asthma Respiratory Asthma
Conditions
Interventions
Patients identified as suitable for the Initial clinic, with a presumed diagnosis of asthma which has not been previously characterized, will be selected from the daily review of ED attendances carrie
Sponsors
Portsmouth Hospitals NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years and above 2. Two or more attendances in ED or frequent unscheduled care visits to the GP within the last 12 months 3. Willing and able to give consent 4. Confirmed diagnosis of asthma
Exclusion criteria
Exclusion criteria: 1. Declined or unable to give consent 2. Aged under 18
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main outcome measure is whether or not the ESMENA education programme can improve adherence, asthma control and quality of life for patients with poorly controlled asthma: 1. Adherence measured using MARS questionnaire at baseline, following completion of the programme and at 6 months post programme 2. Asthma control measured using Asthma Control Questionnaire (ACQ) at baseline, following completion of the programme and at 6 months post programme 3. Quality of life measured using Asthma Quality of Life questionnaire at baseline, following completion of the programme and at 6 months post programme | — |
Secondary
| Measure | Time frame |
|---|---|
| Feasibility outcomes: 1. Characteristics of patients identified as suitable for the ESMENA programme, measured using demographics, smoking status, disease phenotype, baseline medication, at baseline, following completion of the programme and at 6 months 2. Consent rate to research and education programme, measured using number of consents at the end of the study 3. Attendance rates at education sessions, and reasons for decline, measured using number of attendances at baseline, following completion of the programme and at 6 months 4. Topics identified by patients for discussion in the programme (at the asthma clinic and during the education sessions), measured using topics that patient wish to discuss at baseline, following completion of the programme and at 6 months 5. Adherence to programme completion, measured using attendance rates at baseline, following completion of the programme and at 6 months 6. Number of patients requiring further secondary care appointments following ESMENA review, measured using number of patients at baseline, following completion of the programme and at 6 months 7. Extent to which programme targets appropriate patients, measured by identifying reasons which drive repeat unscheduled care attendances with participants, at baseline, following completion of the programme and at 6 months 8. Extent to which programme meets educational needs of participants, measured using ‘Completion of ESMENA Questionnaire’ at baseline, following completion of the programme and at 6 months 9. Patient and staff experience of delivery, acceptability of current programme design and identified areas for improvement, measured using ‘Completion of ESMENA Questionnaire’ at baseline, following completion of the programme and at 6 months Clinical effectiveness: 1. Number of patients requiring changes in disease management, including inhaler technique education, and types of changes required, measured using number of patients requiring change at baseline, following | — |
Countries
England, United Kingdom
Outcome results
None listed